184 related articles for article (PubMed ID: 34402192)
21. Cost-effectiveness of nivolumab plus ipilimumab versus chemotherapy as first-line therapy in advanced non-small cell lung cancer.
Shu Y; Ding Y; Li F; Zhang Q
Int Immunopharmacol; 2023 Jan; 114():109589. PubMed ID: 36700770
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer.
Chu JN; Choi J; Ostvar S; Torchia JA; Reynolds KL; Tramontano A; Gainor JF; Chung DC; Clark JW; Hur C
Cancer; 2019 Jan; 125(2):278-289. PubMed ID: 30343509
[TBL] [Abstract][Full Text] [Related]
23. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
24. Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Resected Stage IIB or IIC Melanoma in the United States.
Zhang S; Bensimon AG; Xu R; Jiang R; Greatsinger A; Zhang A; Fukunaga-Kalabis M; Krepler C
Adv Ther; 2023 Jul; 40(7):3038-3055. PubMed ID: 37191852
[TBL] [Abstract][Full Text] [Related]
25. Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis.
McDermott DF; Shah R; Gupte-Singh K; Sabater J; Luo L; Botteman M; Rao S; Regan MM; Atkins M
Qual Life Res; 2019 Jan; 28(1):109-119. PubMed ID: 30191365
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of Response-Adapted De-escalation of Immunotherapy in Advanced Melanoma.
Cartun Z; Kunz WG; Heinzerling L; Tomsitz D; Guertler A; Westphalen CB; Ricke J; Weir W; Unterrainer M; Mehrens D
JAMA Dermatol; 2022 Dec; 158(12):1387-1393. PubMed ID: 36260321
[TBL] [Abstract][Full Text] [Related]
27. Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis.
Barzey V; Atkins MB; Garrison LP; Asukai Y; Kotapati S; Penrod JR
J Med Econ; 2013; 16(2):202-12. PubMed ID: 23057750
[TBL] [Abstract][Full Text] [Related]
28. Economic evaluation of nivolumab combined with ipilimumab in the first-line treatment of advanced melanoma in Japan.
Paly VF; Hikichi Y; Baker T; Itakura E; Chandran N; Harrison J
J Med Econ; 2020 Dec; 23(12):1542-1552. PubMed ID: 33000994
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective.
Gerbasi ME; Stellato D; Ghate SR; Ndife B; Moynahan A; Mishra D; Gunda P; Koruth R; Delea TE
J Med Econ; 2019 Dec; 22(12):1243-1252. PubMed ID: 31223037
[No Abstract] [Full Text] [Related]
30. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
[TBL] [Abstract][Full Text] [Related]
31. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
32. Cost-Effectiveness of Pembrolizumab as an Adjuvant Treatment in Colombia for Melanoma Patients with Lymph Node Involvement After Complete Resection.
Lopez-Vinueza C; Urrego-Reyes J; Gutierrez FRS; Wurcel V; Zhang S; Jiang S; Jiang R; Zambrano Harvey A; Dhankhar P; Sawhney B; Baluni G; Jain S; Bhadra D
Adv Ther; 2023 Jun; 40(6):2836-2854. PubMed ID: 37129772
[TBL] [Abstract][Full Text] [Related]
33. Adjuvant Therapy of Melanoma.
Tarhini AA
Hematol Oncol Clin North Am; 2021 Feb; 35(1):73-84. PubMed ID: 33759774
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma.
Wu B; Zhang Q; Sun J
J Immunother Cancer; 2018 Nov; 6(1):124. PubMed ID: 30458884
[TBL] [Abstract][Full Text] [Related]
35. Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: a model-based economic evaluation.
Retèl VP; Steuten LMG; Geukes Foppen MH; Mewes JC; Lindenberg MA; Haanen JBAG; van Harten WH
BMC Cancer; 2018 Sep; 18(1):895. PubMed ID: 30219040
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical Trial.
Unger JM; Darke A; Othus M; Truong TG; Khushalani N; Kendra K; Lewis KD; Faller B; Funchain P; Buchbinder EI; Tarhini AA; Kirkwood JM; Sharon E; Sondak V; Guild SR; Grossmann K; Ribas A; Patel SP
JAMA Oncol; 2023 Feb; 9(2):251-260. PubMed ID: 36416836
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of second-line ipilimumab for metastatic melanoma: A real-world population-based cohort study of resource utilization.
Lu B; Dai WF; Croxford R; Isaranuwatchai W; Beca J; Menjak IB; Petrella TM; Mittmann N; Earle CC; Gavura S; Mercer RE; Hanna TP; Chan KKW
Cancer Med; 2023 May; 12(10):11451-11461. PubMed ID: 36999965
[TBL] [Abstract][Full Text] [Related]
38. Multiple treatment comparison of seven new drugs for patients with advanced malignant melanoma: a systematic review and health economic decision model in a Norwegian setting.
Pike E; Hamidi V; Saeterdal I; Odgaard-Jensen J; Klemp M
BMJ Open; 2017 Aug; 7(8):e014880. PubMed ID: 28827234
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer.
Liu Q; Tan C; Yi L; Wan X; Peng L; Li J; Luo X; Zeng X
PLoS One; 2021; 16(11):e0258605. PubMed ID: 34780478
[TBL] [Abstract][Full Text] [Related]
40. Cost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinum Plus Pemetrexed (with and Without Bevacizumab) in Patients with Unresectable Malignant Pleural Mesothelioma in Switzerland.
Barbier MC; Fengler A; Pardo E; Bhadhuri A; Meier N; Gautschi O
Pharmacoeconomics; 2023 Dec; 41(12):1641-1655. PubMed ID: 37572261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]